Adalimumab abs (EIA) (s) (Serum (s))

both sex
	< 6,0 RU/ml
The efficacy of adalimumab therapy depends on various factors, including the development of anti-drug antibodies (ADAs). When a patient does not respond adequately to therapy or the response is deemed insufficient, interpreting their concentrations alongside the corresponding adalimumab trough concentrations can inform therapeutic decisions as follows: Adalimumab trough concentrations within the therapeutic range without detection of ADA: dose intensification on an individualized basis or a switch to another drug group. Adalimumab trough concentrations below the therapeutic range with evidence of ADA: dose intensification/adjustment of the treatment interval and introduction of an immunomodulator (for ADA < 6 RU/ml) or a switch to a drug from the same or a different therapeutic group (for ADA >= 6 RU/ml). Ref.: Papamichael K & Chiefetz AS. Curr Opin Gastroenterol. 2019;35:302., Nice R et al. Aliment Pharmacol Ther. 2021;53:128. Our ADA method detects both free and drug-bound ADAs. For patients taking > 5 mg/day of biotin, samples should be collected at least 24 hours after the last dose.